ZS05
    Zensun is applying the compound ZS-05 towards a new clinical indication: the prevention and treatment of urinary tract infection (UTI). Preliminary in vitro studies with ZS-05 demonstrated that it could induce the production of antimicrobial peptides in a dose dependent manner, and had an obvious bacteriostatic effect against E. coli , enhancing the cell’s innate immunity. Based on these results, Zensun has submitted an IND application to the CFDA for ZS-05. Use of ZS-05 for the prevention and treatment of UTI and its recurrence could significantly reduce the use of antibiotics, the risk of developing drug-resistant bacteria, and the medical cost of the disease.

About Urinary Tract Infection
    UTI is a significant health problem in both community and hospital–based settings, and has become one of the most common bacterial infections, following respiratory and digestive tract infection [1]. Women are more liable to get UTI, especially between 16 and 35 years old. Up to 40-60% of women report having had a UTI at some point in their lives.
    It is estimated that 150 million patients suffering with UTIs occur yearly world-wide, accounting for $6 billion in health care expenditures [2,3]. In the United States, these infections annually account for approximately 7 million office visits and more than 1 million hospitalizations [4].
    An important characteristic of urinary tract infection is the high recurrence rate, which can lead to chronic nephritis and chronic renal failure. Currently, UTIs are mainly treated with antibiotics, but clinical non-standard application of antimicrobial drugs in general has led to an enhanced antimicrobial resistance (AMR), which has evolved to become a worldwide health threat.
    Research in China has indicated that the resistant rates of clinically isolated E. coli strains (the main pathogenic bacteria for urinary tract infection) were 50% or more for the first-line treatment drugs Fluoroquinolone, Gentamicin and Piperacillin; and 31% and 71%, respectively, for amoxicillin/clavulanic acid and compound sulfamethoxazole [5,6].
    Furthermore, research and development on new antibiotics has not generated a major breakthrough in the past 30 years [7]. Once the AMR of pathogenic bacteria strengthens, antibiotics treatments for infections are of less effect when an infection recurs.
 
Clinical Trials Recruiting Participants